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Heparanase and macrophage 
interplay in the onset of liver 
fibrosis
Maria Francesca Secchi1,2, Marika Crescenzi2, Valentina Masola1,3, Francesco Paolo Russo2, 
Annarosa Floreani2 & Maurizio Onisto  1
The heparan sulfate endoglycosidase heparanase (HPSE) is involved in tumor growth, chronic 
inflammation and fibrosis. Since a role for HPSE in chronic liver disease has not been demonstrated 
to date, the current study was aimed at investigating the involvement of HPSE in the pathogenesis 
of chronic liver injury. Herein, we revealed that HPSE expression increased in mouse livers after 
carbon tetrachloride (CCl4)-mediated chronic induction of fibrosis, but with a trend to decline during 
progression of the disease. In mouse fibrotic liver tissues HPSE immunostaining was restricted in 
necro-inflammatory areas, co-localizing with F4/80 macrophage marker and TNF-α. TNF-α treatment 
induced HPSE expression as well as HPSE secretion in U937 macrophages. Moreover, macrophage-
secreted HPSE regulated the expression of α-SMA and fibronectin in hepatic stellate LX-2 cells. Finally, 
HPSE activity increased in the plasma of patients with liver fibrosis but it inversely correlated with 
liver stiffness. Our results suggest the involvement of HPSE in early phases of reaction to liver damage 
and inflammatory macrophages as an important source of HPSE. HPSE seems to play a key role in the 
macrophage-mediated activation of hepatic stellate cells (HSCs), thus suggesting that HPSE targeting 
could be a new therapeutic option in the treatment of liver fibrosis.
Chronic liver injury is characterized by necrosis and inflammation, which trigger fibrosis and may eventually lead 
to cirrhosis and organ functional failure. Activated Kupffer cells and hepatic stellate cells (HSCs) are the main cell 
types involved in the pathogenesis of liver fibrosis. Kupffer cells promote inflammatory and fibrogenic responses 
by releasing cytokines, chemokines and growth factors that exacerbate inflammation and trigger the activation of 
HSCs, a central event during liver fibrosis. Quiescent HSCs are activated into fibrogenic α-SMA positive myofi-
broblasts by a plethora of paracrine and autocrine stimuli and they profoundly alter the microenvironment by the 
secretion of excessive extracellular matrix (ECM) proteins (collagens, fibronectin, laminin). All these events aim 
at recovering and maintaining organ functions but, when deregulated by prolonged injury, result in uncontrolled 
fibrogenesis, ECM accumulation and disrupted organ architecture1–4.
In mammals, among the enzymes that degrade ECM and basal membranes, heparanase (HPSE) is the only 
one with the ability to degrade heparan sulfate (HS) chains of heparan sulfate proteoglycans (HSPGs), gener-
ating fragments of about 5–7 kDa. At intracellular level (endosomal and lysosomal), HPSE participates in the 
turnover of membrane-associated HSPGs, while the secreted enzyme is involved in the remodeling and degra-
dation of ECM5,6. In physiological conditions, HPSE expression is tightly regulated to prevent uncontrolled HS 
cleavage and adverse biological effects. Conversely, HPSE expression is up-regulated in several pathologies7–9. 
It is well accepted that HPSE enzymatic activity contributes to glomerular basement membrane disassembly 
and proteinuria in several experimental and human glomerulopathies10–13 as well as to sustain angiogenesis 
and tumor cell migration in cancer progression14–16. Interestingly, recent findings on inflammatory disorders 
of the intestinal tract have also pointed to HPSE as an important link between inflammation and cancer17,18. 
Beyond matrix remodelling, extracellular HPSE activity affects both physiological and pathological processes if 
considering the broad range of molecules (growth factors, cytokines, chemokines and enzymes) that negatively 
charged HS bind and that are left to diffuse upon HPSE cleavage15,19,20. Increased HPSE activity at renal tubu-
lar level was demonstrated to regulate epithelial-to-mesenchymal transition (EMT) of proximal tubular cells, 
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creating a pro-fibrotic milieu. Indeed, we have recently shown that, by regulating the availability and activity of 
growth factors (i.e. FGF-2 and TGF-β), HPSE promotes tubular EMT and kidney fibrosis21,22. Consistently, in the 
streptozotocin-induced diabetic nephropathy model, HPSE-KO mice showed less interstitial fibrosis compared 
to untreated mice23.
Although the role of HPSE as a pro-cancerous agent has been widely characterized in hepatocarcinoma 
(HCC)24–26, its involvement in non-cancerous chronic liver disease is poorly understood thus far and contro-
versial results have been obtained both from human tissues and animal models of liver fibrosis. The comparison 
performed by Xiao et al. on HPSE expression in normal, cirrhotic and cancer livers did not reveal significant dif-
ferences in mRNA and protein levels between normal and cirrhotic tissues compared with the increased levels in 
HCC tissue24. Surprisingly, Ikeguchi et al. found a decreased amount of HPSE mRNA in HCC tumors compared 
to adjacent non-cancerous tissue. Moreover, HPSE expression in non-cancerous tissue was found to negatively 
correlate with fibrosis stage27. Two different experimental studies demonstrated increased HPSE protein levels 
in the fibrotic liver of thioacetamide-treated rats although discordant results regarding the fibrotic stage of the 
up-regulation emerged and no deep investigation in HPSE regulation and possible effects were performed28,29.
In the current study, to shed light on HPSE involvement in liver fibrosis, the tempo-spatial pattern of HPSE 
expression in the well-established animal model of CCl4-induced fibrosis was investigated. The evidence from 
in vivo data, demonstrating increased HPSE expression in the early phases of chronic disease, prompted us to 
examine the cellular mechanism involved in such a condition. A role for inflammatory macrophages in mediating 
HPSE accretion was demonstrated as well as HPSE effects on HSCs activation were addressed. To translate our 
observation, HPSE activity was also investigated in the plasma of patients with chronic liver diseases at different 
stages.
Results
HPSE was up-regulated in mice with early chronic liver injury. The tempo-spatial expression of 
HPSE in liver fibrosis was studied in mice chronically intoxicated with CCl4, which represent a well establish 
model of fibrosis induction. To evaluate the outcome of the treatment in terms of histopathological changes 
and hepatic fibrosis, H&E and Azan-Mallory stainings were respectively performed on control and CCl4-treated 
livers. Normal lobular architecture and strictly vascular distribution of collagen fibers were observed in liver 
sections from control mice at each point in time. Periodic administration of CCl4 in mice caused massive centri-
lobular hepatic inflammation and necrosis accompanied by perisinusoidal fibrosis in early chronic injured livers. 
Liver tissues from 8 and 12 week CCl4-treated mice showed mild cell infiltration, pseudolobules formation and 
bridging fibrosis (Fig. 1a, upper panels). Immunostaining for α-SMA marked vascular smooth muscle cells in 
control livers while activated HSCs at the site of injury and in correspondence to fibrotic septa were detected after 
CCl4 treatment (Supplementary Fig. S1). After 1 and 2 weeks of CCl4 exposure, the expression of hepatic HPSE 
was found increased, as determined by immunohistochemistry whereas a weak positivity was observed after 8 
and 12 weeks. In addition, immunostaining for HPSE revealed a centrilobular localization, nearby necrotic areas 
with perisinusoidal fibrosis and inflammatory cell infiltrate (Fig. 1a, lower panels). As shown in Fig. 1b, hepatic 
HPSE mRNA levels were significantly up-regulated in the liver of mice with early chronic disease but not in mice 
with advance disease, compared with control animals. Moreover, HPSE mRNA levels were significantly reduced 
in livers of 2 week- compared to 1 week-treated group. In line with real-time RT-PCR data, HPSE protein level 
reached a peak at 1 and 2 weeks of CCl4 injection while declining at 8 and 12 weeks of treatment (Fig. 1c).
HPSE co-localized with macrophages in early chronic CCl4-injured livers. Starting from the 
observation that HPSE was localized mainly around the necro-inflammatory areas, we speculated that liver mac-
rophages could be a putative cell source of HPSE in toxic injured liver. To investigate whether macrophages could 
be involved in the HPSE up-regulation, a double immunofluorescence staining for HPSE and F4/80 (a mouse 
macrophage-specific marker) was performed in early chronic CCl4-injured livers. In healthy mouse livers, F4/80 
decorated resident Kupffer cells lining hepatic sinusoids (Fig. 2a). In the livers of mice treated for 1 and 2 weeks 
with CCl4, we detected enhanced F4/80 immunoreactivity indicating an increased macrophages infiltration. 
HPSE immune-labelling strongly co-localized with F4/80 after 1 and 2 weeks of CCl4 administration, consistent 
with our hypothesis that macrophages are a relevant source of HPSE in CCl4-injured liver (Fig. 2b).
Immune regulation of HPSE expression in macrophages. To gain insight into the mechanism of 
HPSE immune regulation upon liver injury TNF-α and IL-1β, the main pro-inflammatory mediators in the initial 
phase of hepatic injury, and TGF-β, as an anti-inflammatory cytokine, were tested on U937 macrophages to meas-
ure HPSE expression. TNF-α treatment induced a significant up-regulation of HPSE expression, both at mRNA 
and protein levels (Fig. 3a,b). We also proved that HPSE protein was undetectable in the conditioned medium of 
U937 cells but it was released in response to TNF-α stimulation (Fig. 3c). Differently from TNF-α, IL-1β did not 
affect HPSE mRNA levels (Fig. 3a). Data on IL-1β were also confirmed in RAW 264.7 cell line (data not shown). 
U937 treated with TGF-β significantly increased HPSE mRNA levels (Supplementary Figure S2a). Moreover, 
TGF-β induced the secretion of HPSE in the medium of U937 (Supplementary Figure S2b). To further confirm 
our observations, TNF-α and TGF-β mRNA expression were measured in the fibrotic livers of mice treated with 
CCl4. Compared to control mice, in CCl4-injured livers TNF-α mRNA levels were up-regulated at 1 week and at 2 
weeks. On the contrary, no statistically significant difference was found after 8 weeks and 12 weeks of CCl4 treat-
ment (Fig. 4a). Similar results were observed for TGF-β (Supplementary Figure S3). Moreover, HPSE co-localized 
with TNF-α in fibrotic mouse livers after 1 and 2 weeks of CCl4 administration (Fig. 4b).
Inhibition of HPSE attenuated macrophage-mediated HSCs activation. To understand whether 
macrophage-derived HPSE could be a regulator of HSCs activation, LX-2 cells were grown in the conditioned 
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medium of U937 macrophages pre-treated with or without TNF-α to induce HPSE expression. To verify the 
influence of HPSE on cell activation, U937 conditioned medium was added in the presence or absence of the 
heparin-derived HPSE inhibitor SST0001 (Fig. 5a). The conditioned medium of TNF-α-activated macrophages 
induced a significant up-regulation of α-SMA and fibronectin mRNA levels as compared to treatment with the 
conditioned medium of untreated U937. However, when LX-2 cells were treated with the conditioned medium 
of TNF-α-activated macrophages in combination with SST0001, the increases of both α-SMA and fibronectin 
mRNA were significantly diminished (Fig. 5b,c). These transcriptional data were also confirmed at protein level 
Figure 1. Liver fibrosis and expression of HPSE in mice with CCl4-induced chronic liver disease. (a) 
Histological assessment of CCl4-induced liver fibrosis through H&E staining (upper panels) and Azan-Mallory 
staining (medium panels) of control and CCl4-injured livers at the indicated time of treatment. Lower panels 
show immunohistochemistry for HPSE on liver sections from control and CCl4-treated mice at the indicated 
time points. Scale bars = 100 μm. (b) HPSE mRNA expression in livers from control and CCl4-treated mice for 
the indicated time, measured by real-time RT-PCR analysis and normalized to GAPDH. Error bars represent 
s.e.m., n = 3, ***p < 0.001, **p < 0.01. (c) Western blot analysis for HPSE on whole liver protein extracts 
from CCl4-induced fibrotic mice and control mice. Coomassie blue staining was used as a loading control 
(Supplementary Fig. S5). Full-length blots are presented in Supplementary Fig. S6.
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by Western blot analyses (Fig. 5e,f). In contrast to α-SMA and fibronectin, no significant difference was observed 
in the expression of the HSCs marker collagen 1(α1), both in the presence or absence of SST0001 (Supplementary 
Fig. S4). Among soluble mediators, VEGF is one of the major growth factors expressed and secreted by acti-
vated HSCs30. Since HPSE is known to regulate VEGF expression31,32, we investigated if HPSE could also mod-
ulate VEGF transcription in HSCs. The expression of VEGF increased in LX-2 stimulated with the conditioned 
medium of TNF-α activated U937 vs. cells stimulated with the conditioned medium of untreated U937. The 
addition of SST0001, however, did not affect VEGF expression, as observed both at mRNA and protein levels 
(Fig. 5d, 5g). These results imply that HPSE may modulate HSCs activation and highlight a new mechanism by 
which inflammatory macrophages control HSCs activity.
HPSE plasma activity inversely correlated with human liver stiffness. To further investigate the 
role of HPSE in the development of liver fibrosis, we studied and correlated HPSE activity measured in the plasma 
of patients with chronic liver disease and the stage of the disease itself, assessed by transient elastography. HPSE 
plasma activity was higher in patients with autoimmune liver disease at F0-F1 and F2-F3 stages of fibrosis with 
respect to healthy control group and these increases were statistically significant. However, HPSE plasma activity 
did not increase in patients with F4 fibrosis stage compared to controls. In patients with chronic viral hepa-
titis, HPSE plasma activity was elevated in F0-F1 and F2-F3 fibrotic compared to healthy controls and these 
increases were statistically significant. As observed in patients with autoimmune liver diseases, F4 fibrotic patients 
affected by hepatitis C (HCV) and hepatitis B (HBV) also had basal plasma HPSE activity (Fig. 6a). In addition, an 
inverse correlation of HPSE activity with organ stiffness was found, both in autoimmune liver diseases (R = 0.23, 
p = 0.002) and viral hepatitis (R = 0.24, p = 0.004) (Fig. 6b).
Discussion
As an ECM remodeling enzyme with the ability to cleave HS chains, HPSE is determinant in those processes 
that require cell movement and growth factors bioavailability (embryogenesis, angiogenesis and tumor pro-
gression)8,9. Interest in HPSE in acute and chronic inflammatory disease and cancer-related inflammation has 
increased in the last decade and has led to the discovery of novel pro-inflammatory and pro-fibrogenic roles for 
this enzyme6,33,34. Interesting data have emerged from chronic colitis and diabetic nephropathy mouse mod-
els, both supporting the hypothesis that a chronic inflammatory circuit, connecting injured epithelial cells and 
Figure 2. HPSE co-localization with F4/80 in early CCl4-injured liver tissues. (a) Confocal 
immunofluorescence staining for F4/80 on control livers showing Kupffer cells lining sinusoid. White arrows 
indicate representative cells. (b) Representative image of confocal double immunofluorescence staining for 
HPSE (green) and F4/80 (red) on early chronic CCl4-injured livers (1 week of CCl4 administration). Cell 
nuclei were counterstained with Hoechst (blue). Insert shows high magnification from the white box. Scale 
bars = 20 μm.
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inflammatory macrophages, is mediated by HPSE17,35. Taken together, these investigations have highlighted the 
role of HPSE in sustaining inflammation and fibrosis, which we hypothesized could be translated to the liver 
context. Specifically, we questioned whether HPSE could be up-regulated in or by injured liver and which could 
be the implications for liver fibrogenesis. With a set of in vivo, in vitro and ex vivo experiments, we provided 
evidence that HPSE was crucially involved in the establishment of chronic liver injury. Indeed, our data showed 
that HPSE underwent up-regulation both at gene and protein level in liver tissue of early chronic CCl4-treated 
mice but progressively decreased in the course of liver injury. Interestingly, HPSE levels did not increase con-
comitantly with the development of fibrosis. This trend in HPSE expression suggests that this protein could be 
involved in the first stage of liver disease onset. HPSE expression was also restricted in terms of spatial distribu-
tion, being detected at the necrotic and inflamed centrilobular zones and where it localized with macrophages. 
Thus, at variance from inflammatory bowel diseases and diabetic nephropathy where HPSE increase is preferen-
tially sustained by injured epithelial cells11,17,35,36, in our model HPSE was primarily expressed by inflammatory 
macrophages in the early phase of chronic liver injury. As far as the decline of HPSE in late fibrotic stages is 
concerned, we hypothesized a switching-off mechanism which could occur in macrophages according to their 
plastic phenotype. In addition, it would be interesting to analyze in depth whether other different inflammatory 
Figure 3. TNF-α regulation of HPSE expression and secretion in U937 macrophages. (a) U937 cells were 
treated with IL-1β and TNF-α for 24 h. The expression of HPSE was assessed by real-time RT-PCR and 
normalized to GAPDH. Error bars represent s.e.m., n = 3, **p < 0.01. (b) Western blot analysis for HPSE on 
lysates from control and TNF-α-treated U937 cells. Error bars represent s.e.m., n = 3, *p < 0.05. Full-length 
blots are presented in Supplementary Fig. S7. (c) Western blot analysis for HPSE on conditioned medium from 
control and TNF-α-treated U937 cells. Full-length blot is presented in Supplementary Fig. S8.
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cell types, which participate in the initiation of liver fibrosis, could be a source of HPSE. In this view, neutrophils 
are an interesting cell population to be analyzed further, due to their critical but redundant role both in acute and 
chronic liver damage37,38. However, considering published data on the role of this population in also repairing 
chronic injured tissues and on macrophages-neutrophil mutual exclusive presence in the reparative phase39,40, it 
Figure 4. HPSE co-localization with TNF-α in early CCl4-injured liver tissues. (a) TNF-α mRNA expression 
in livers from control and CCl4-treated mice, measured by real-time RT-PCR and normalized to GAPDH. 
Error bars represent s.e.m., n = 3, **p < 0.01, *p < 0.05. (b) Representative image of confocal double 
immunofluorescence staining for TNF-α (red) and HPSE (green) on early chronic CCl4-injured livers (1 week 
of CCl4 administration). Cell nuclei were counterstained with Hoechst (blue). Scale bar = 20 μm.
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would be interesting to analyze in our model if the decrease in macrophage-derived HPSE is associated with a 
massive neutrophils presence.
A pro-fibrogenic role of HPSE has been demonstrated in kidney and, more recently, in intestine23,41. The 
observation of enhanced HPSE expression in the early stages of chronic liver disease led us to wonder what its 
role could be in the process of hepatic fibrogenesis and, consequently, the possible mechanism at the basis of this 
pathological event. In the initial phase of hepatic injury, Kupffer cells react to parenchymal damage by secreting 
inflammatory mediators (mainly TNF-α, IL-1β and TGF-β) that perpetuate inflammation and hepatocellular 
damage42. Here we proved that TNF-α, as well as TGF-β, but not IL-1β, increased HPSE production as well as its 
release by macrophages. Our data further support the ability of both TNF-α and TGF-β to induce HPSE expres-
sion and secretion that was already observed in endothelial cells43 and epithelial cells17,22. In a model of chronic 
Figure 5. HPSE regulation of HSCs activation. (a) Experimental protocol of conditioned medium experiment. 
U937 macrophages were incubated without or with TNF-α for 24 h after which they were maintained 24 h in 
medium without serum. Conditioned media from untreated (CM) and pre-treated (CM (TNF-α)) U937 were 
collected and transferred to serum starved LX-2 cells. Conditioned medium from pre-treated U937 was added 
without or with SST0001. The expression of α-SMA, fibronectin and VEGF-A was detected in LX-2 treated with 
CM and CM (TNF-α) ± SST0001 by real-time RT-PCR (b,c,d) and Western blot (e,f,g). Error bars represent 
s.e.m., n = 3, **p < 0.01, *p < 0.05. Original blots are presented in Supplementary Fig. S9.
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colitis, Lerner et al. showed that macrophage-derived TNF-α induced HPSE expression in colon epithelium 
which, in turn, fostered macrophage activation17. In our model this is not verified. Indeed, two in vivo observa-
tions (first, TNF-α up-regulation, in line with HPSE expression, in injured liver only at 1 and 2 weeks of treat-
ment and second, TNF-α strong immuno-colocalization with HPSE) together demonstrated a role for TNF-α 
in regulating HPSE expression in macrophages themselves and allow us to suppose that there is an autocrine 
loop between TNF-α and HPSE to maintain macrophage activation. Considering TGF-β modulation during 
the chronic liver injury, the role of TGF-β in HPSE modulation and in relation to TNF-α is under investigation.
In the complex cellular cross-talk that characterizes chronic liver injury, activated macrophages are a stim-
ulus for HSCs activation at early steps, by the release of pro-fibrogenic growth factors2. Considering the ability 
of HPSE to regulate the availability of many HS-linked molecules20, the activity of macrophage-derived HPSE 
was also expected to modulate HSCs activation. Indeed, we provided evidence that HPSE participated in the 
up-regulation of fibrogenic markers α-SMA and fibronectin, but not collagen 1(α1), by activated LX-2 cells. 
These data further strengthened the pro-fibrogenic role of HPSE that we had already demonstrated in kidney 
fibrosis, in which, through the regulation of pro-fibrotic factor bioavailability, it modulates mesenchymal marker 
expression sustaining tubular transdifferentiation and fibrosis21,22. The fact that the inhibition of HPSE by means 
of SST0001 did not alter the expression of VEGF-A suggested to us that HPSE is not a direct regulator of stellate 
cells VEGF-A expression, but rather that other molecules released by activated macrophages in the microenvi-
ronment could participate in the pro-angiogenic behaviour of HSCs.
Considering the transient HPSE expression observed in the CCl4 mouse model of liver fibrosis, in the ex 
vivo part of this work HPSE activity was measured in the plasma of healthy subjects and patients with chronic 
liver disease at various stages of fibrosis, of viral or autoimmune etiology. HPSE activity was found elevated in 
the plasma of patients with mild, significant and severe fibrosis, whereas it decreased to basal levels in cirrhotic 
Figure 6. HPSE plasma activity in patients with chronic liver diseases and its correlation with liver stiffness. (a) 
Box-plot of HPSE activity in the plasma of healthy controls (HC) (n = 14) and patients with autoimmune liver 
diseases (n = 35) and viral hepatitis (n = 30). Patients were staged from F0 to F4. Squares represent mean values. 
***p < 0.001, **p < 0.01, *P < 0.05. (b) Scatter-plots of HPSE activity quantified in the plasma of patients with 
autoimmune liver diseases (left) and viral hepatitis (right) and correlated to liver stiffness. Trend lines were 
reported.
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patients. Moreover, it is noteworthy that an inverse correlation between HPSE activity and liver stiffness was 
demonstrated in this cohort of patients. These findings strongly supported the in vivo data from the CCl4-animal 
model of fibrosis and provide further evidence of an early role played by HPSE in the establishment of an hepatic 
disease. The fact that these results were observed in patients with both autoimmune liver disease and viral hepa-
titis suggests that the pathological events that are at the basis of HPSE up-regulation are probably the same inde-
pendently of the etiology of liver disease.
Collectively, our supposed model of cascade of events can be summarized as follows. In response to injury, 
activated macrophages trigger inflammation by the secretion of inflammatory cytokines and chemokines. Among 
these, TNF-α, acting on macrophages themselves, induces the expression and secretion of HPSE. We hypothe-
size that macrophage-derived HPSE may sustain early steps of fibrogenesis through HSCs activation. It could 
also be plausible that HPSE enhances Kupffer cell activation since a role for HPSE in sensitizing macrophages 
to activation recently emerged in different inflammatory conditions17,35, involving both HS cleavage44,45 and 
non-enzymatic activity46. Further studies need to be performed to confirm the biological significance and the 
functional role of HPSE in chronic liver disease, especially in relation to macrophages as the main source of 
bioavailability. Furthermore, a deep analysis of fibrosis establishment in a mouse model of chronic liver injury in 
which an inhibitor for HPSE is used in a preventive setting is mandatory. The fact that HPSE seems to be involved 
in the initial steps of the disease acquires even more relevance if considering that the probability of liver fibro-
sis resolution decreases with advanced disease1. Bearing in mind the experimental evidences arising from our 
study, HPSE could be considered an early possible pharmacological target in the prevention of fibrosis establish-
ment. Considering that several HPSE inhibitors are currently undergoing clinical trials and have demonstrated 
anti-tumor efficacy and few side effects, the results of this study strongly encourage a possible future use of these 
drugs in the treatment of liver fibrosis as well. A graphical abstract representing the hypothesised mechanism of 
action of HPSE in liver fibrosis and its role as a possible therapeutic target is shown in Fig. 7.
Methods
Animals. Twenty male Balb/cJ mice, 6 weeks old, were maintained in a pathogen-free and temperature-con-
trolled environment at 12 h light/dark cycle and were fed with a standard rodent diet and water ad libitum. Animal 
studies followed the guidelines of the National Institutes of Health (CEASA protocol number 108288/2013, 
approved by the Ethics Committee of the University of Padova, Italy).
Experimental model of liver fibrosis. Mice were randomly divided into CCl4-treated (n = 12) and control 
(n = 8) groups. Animals were intraperitoneally injected with a mixture 1:7 of CCl4 (Sigma-Aldrich, Milan, Italy) 
in olive oil, at a dose of 1,2 μL/g body weight twice a week and sacrificed after 1, 2, 8 and 12 weeks from the begin-
ning of the treatment. Control mice received intraperitoneal injections of oil. Animals (2 controls and 3 treated 
mice at each time point) were sacrificed and livers were harvested 72 h after the last injection of CCl4.
Histopathology. Mouse liver tissue was formalin-fixed and paraffin-embedded. Five μm thick sections were 
stained with Hematoxylin-Eosin (H&E) and Azan-Mallory according to standard protocols.
Figure 7. Mechanism of action of HPSE in liver fibrosis dynamics. In response to a chronic insult, hepatic 
Kupffer cells (KC) activate secreting inflammatory cytokines. Among them, TNF-α is the most critical in 
sustaining a positive loop of Kupffer cell activation. This leads to secretion of HPSE by macrophages which, in 
turn, regulates the activation of stellate cells (HSC) into myofibroblasts (MFB) to the extent of determining a 
dramatic alteration in extracellular matrix (ECM) composition. The inhibition of HPSE by a molecular drug 
could be a therapeutic strategy to counteract fibrosis onset.
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Cell culture. U937 human monocyte and LX-2 human HSCs cell lines were cultured in RPMI-1640 medium 
(Euroclone, Milan, Italy) supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 100 U penicillin and 
100 μg/mL streptomycin. Prior to each experiment, U937 suspension monocytes were differentiated in adherent 
macrophages by treatment with 20 ng/mL phorbol myristate acetate (PMA, Sigma-Aldrich, Saint Louis, Missouri, 
USA) for 48 h. U937 macrophages were serum starved and treated with 10 ng/mL TNF-α (T6674, Sigma-Aldrich) 
and 10 ng/mL active IL-1β (200-01B, Peprotech, London, UK). TGF-β (#8915, Cell Signaling Technology, Leiden, 
The Netherlands) was used at 20 ng/mL. For conditioned media experiments, U937 macrophages were seeded in 
100 mm dishes and serum starved for 24 h. Cells were treated with or without TNF-α (10 ng/mL) for 24 h after 
which medium was replaced with fresh medium without serum for another 24 h. Conditioned media were col-
lected, filtered (0.22 μm) and used to treat LX-2 cells in the presence or absence of the HPSE inhibitor SST0001 
(500 μg/mL), a non-anticoagulant 100% N-acetylated, 25% glycol-split heparin (Leadiant Biosciences Ltd).
Western blot. Snap-frozen liver samples were homogenized in RIPA buffer (150 mM NaCl, 1% Triton X-100, 
0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris-HCl, pH 8) supplemented with Protease Inhibitor Cocktail 
(Sigma-Aldrich). Cells were homogenized in lysis buffer containing 1% Triton, 150 mM NaCl, 20 mM Tris-HCl, 
pH 7.5. Protein concentration was determined using a bicinchoninic acid assay kit (Thermo Scientific Pierce 
BCA Protein Assay Kit, Thermo Scientific, Rockford, USA). Equal amounts of protein lysate or equal volumes 
of conditioned media were mixed with Laemmli loading buffer and heated at 100 °C for 10 min. Proteins were 
subjected to SDS-PAGE on 10% acrylamide gel and electro-transferred to a nitrocellulose membrane (Sartorius 
AG, Goettingen, Germany). Membranes were blocked with 5% non-fat milk in Tris buffered saline with 0,1% 
Tween-20 (0,1% TBST) and incubated with primary antibody overnight at 4 °C. After washing with TBST, 
membranes were incubated with horseradish peroxidase (HRP)-conjugated secondary antibody for 90 min at 
room temperature (RT). Detection was performed using a chemiluminescence substrate with Alliance system 
(UVItec, Cambridge, UK). The following primary antibodies were used: anti-human HPSE (ANT-193, ProSpec, 
Ness-Ziona, Israel), anti-mouse HPSE (sc-25826, Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-VEGF 
(sc-152, Santa Cruz Biotechnology), anti-α-SMA (A5228, Sigma-Aldrich), anti-fibronectin (sc-9068, Santa Cruz 
Biotechnology) and anti-GAPDH (sc-25778, Santa Cruz Biotechnology). The following secondary antibodies 
were used: goat anti-rabbit IgG-HRP and goat anti-mouse IgG-HRP (sc-2004 and sc-2005 respectively, Santa 
Cruz Biotechnology).
Immunohistochemistry. After deparaffinization, antigen unmasking was performed by heating slices in 
sodium citrate buffer (10 mM sodium citrate, 0.05% Tween-20, pH 6), in a microwave oven twice for 5 min. Slices 
were left 30 min at RT and washed 3 times for 5 min in dH2O. Inactivation of endogenous peroxidase was per-
formed by using 3% H2O2 for 10 min. After washing with 0.1% TBST, sections were saturated with 5% goat serum 
in 0.1% TBST for 90 min at RT and incubated with primary antibody anti-HPSE (sc-25826, Santa Cruz) diluted 
1:300 in antibody buffer (2.5% goat serum in 0.1% TBST) overnight at 4 °C. Then, slices were rinsed three times 
with 0.1% TBST for 5 min and incubated with a biotinylated goat anti-rabbit IgG secondary antibody (BA-1000, 
Vector laboratories) diluted 1:200 in antibody buffer for 30 min at RT. After washing with 0.1% TBST, sections 
were incubated with Streptavidin-HRP conjugate (Sigma-Aldrich) diluted 1:100 for 30 min. For signal detec-
tion, enzymatic reaction was developed using a substrate diaminobenzidine (DAB) solution (Sigma-Aldrich) 
for 1 min. Nuclei were counterstained with hematoxylin. Bright-field images were acquired using a Leica DMR 
microscope.
Immunofluorescence. After deparaffinization and antigen unmasking, liver sections were permeabilized 
with 0.2% Triton X-100 in PBS for 10 min at RT and blocked in PBS supplemented with 1% BSA and 0.1% Triton 
X-100 for 1 h at RT. For double immunofluorescence, slices were incubated overnight at 4 °C with anti-HPSE anti-
body (sc-25826, Santa Cruz) in combination with anti-F4/80 (ab186073, Abcam, Cambridge, UK) or anti-TNF-α 
(sc-1350, Santa Cruz Biotechnology) antibodies. A5228 antibody (Sigma-Aldrich) was used for α-SMA detec-
tion. Antibodies were prepared in PBS supplemented with 1% BSA and 0.3% Triton X-100. Goat anti-rabbit Alexa 
Fluor 488, goat anti-chicken Alexa Fluor 546, donkey anti-goat Alexa Fluor 633 (A-11034, A-11040 and A-21082 
respectively, Thermo Scientific) and goat anti-mouse Alexa Fluor 594 (ab150116, Abcam) were used as secondary 
antibodies. Nuclei were counterstained with Hoechst for 20 min at RT. Images were acquired using a confocal 
microscope Leica TCS SP5.
Real-time reverse transcriptase-PCR. Total RNA from liver tissue and cell cultures was extracted using 
TRIzol reagent (Sigma-Aldrich), according to the manufacturer’s instructions. Five hundred ng of total RNA 
were reverse-transcribed using SuperScript II Reverse Transcriptase (Invitrogen, Carlsbad, USA) according to the 
manufacturer’s instructions. Quantitative real-time reverse transcriptase-polymerase chain reaction (real-time 
RT-PCR) was performed on the ABI 7900HT Fast system (Applied Biosystem, Milan, Italy) using a SYBR-Green 
Master Mix (BIOLINE, London, UK). Each reaction mix was processed using the following PCR conditions: 
polymerase activation at 95 °C for 2 min followed by 40 cycles of 95 °C for 5 sec (denaturation) and 60–62 °C 
for 20 sec (combined annealing/extension). Gene expression was normalized to GAPDH and quantified by the 
ΔΔCT method. All reactions were performed in duplicates for each sample. Primer sequences are reported in 
Table 1.
Human subjects. Seventy-nine subjects were consecutively enrolled in the study. Fourteen healthy vol-
unteers (controls) and 65 patients with different chronic liver diseases were included. Patients were diagnosed 
for HBV (n = 7), HCV (n = 23), primary biliary cholangitis (PBC, n = 17), primary sclerosing cholangitis (PSC, 
n = 9), autoimmune hepatitis (AIH, n = 6), PBC/AIH overlap (n = 2), PSC/AIH overlap (n = 1), according to the 
European Association for the Study of the Liver (EASL) guidelines. Patients with HCV and HBV were categorized 
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in viral hepatitis subgroup. Patients with PBC, PSC, AIH and overlap syndromes were categorized in autoimmune 
disease subgroup. The stage of liver fibrosis was assessed by transient elastography (Fibroscan, Echosens, Paris, 
France). The study was conducted according to the Declaration of Helsinki. All patients gave written consent for 
data collection and sample analysis. The study was approved by the Padua University-Hospital ethical committee 
(protocol number: 3212/A0/14).
Plasma collection. A total of 3 mL of peripheral blood were collected from patients and healthy subjects. 
Blood was processed by centrifugation at 1500 × g for 15 min. Plasma were collected, aliquoted and stored at 
−20 °C until use.
HPSE activity assay. HPSE plasma activity was measured using an ELISA-modified assay performed on 
plates covered with Matrigel (BD Bioscience, Erembodegem, Belgium), as previously described47.
Statistical analysis. Data were reported as means ± standard error of the mean (s.e.m.). For comparison 
between two distributions, the two-tailed t-test was used. For multiple comparisons, the one-way analysis of 
variance (ANOVA) was used. Statistical analyses on real time RT-PCR data were performed using the Relative 
Expression Software Tool (REST). p-values < 0.05 were considered statistically significant.
Data availability. All data generated or analysed during this study are included in this published article (and 
its Supplementary Information files).
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